| __timestamp | Protagonist Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 59644696 |
| Thursday, January 1, 2015 | 2963000 | 79541000 |
| Friday, January 1, 2016 | 6961000 | 98015000 |
| Sunday, January 1, 2017 | 11779000 | 103958000 |
| Monday, January 1, 2018 | 13697000 | 103654000 |
| Tuesday, January 1, 2019 | 15749000 | 128951000 |
| Wednesday, January 1, 2020 | 18638000 | 135799000 |
| Friday, January 1, 2021 | 27196000 | 149883000 |
| Saturday, January 1, 2022 | 31739000 | 220206000 |
| Sunday, January 1, 2023 | 33491000 | 265542000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Protagonist Therapeutics, Inc. and Travere Therapeutics, Inc., from 2014 to 2023.
Over the past decade, Travere Therapeutics has consistently outpaced Protagonist Therapeutics in SG&A spending, with expenses peaking at approximately 265% higher in 2023. This trend underscores Travere's aggressive market strategies and expansive operational framework. Meanwhile, Protagonist Therapeutics has shown a steady increase, with a notable 80% rise in SG&A expenses from 2014 to 2023.
Understanding these financial dynamics is crucial for stakeholders and investors aiming to gauge the strategic priorities and operational efficiencies of these biotech firms. As the industry continues to grow, monitoring such financial metrics will be key to predicting future market movements.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.
Novo Nordisk A/S and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Travere Therapeutics, Inc.
Viatris Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights